Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
More News related to DNDN
- Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
- Dendreon (DNDN) January volatility at 58, May at 99 into meeting
- Dendreon Corp. (DNDN) Receives U.S. FDA Complete Response for PROVENGE CRPC Treatment
- Dendreon Receives FDA Acknowledgement of Complete Response
- Leerink Says Takeaway From Dendreon's (DNDN) Q3 Report is the Busy Preparations for Provenge
More News related to FDA
- Phoenix Tech. (PTEC) Reaches Agreement with RCG Starboard Advisors, Adding 5 Directors to Board; Jeff Smith Named as Chairman
- Walgreens (WAG) Announces Retirement of Three Board Members
- Solarfun Power (SOLF) Appoints Gareth Kung to CFO
Dendreon (Nasdaq: DNDN) Completes Submission of Biologics License Application for PROVENGE
Related Categories
FDAHot List
Stocks Mentioned
+0.49Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
